Business
Incannex Strengthens Clinical Development Pathway for IHL-42X Following Positive Phase 2 Outcomes
Enhanced Phase 2 dose-optimization study designed to accelerate development and support a streamlined Phase 3 program MELBOURNE, Australia and NEW YORK, March
About this update from Incannex Healthcare Inc.
[{"type":"text","content":"Enhanced Phase 2 dose-optimization study designed to accelerate development and support a streamlined Phase 3 program\nMELBOURNE, Australia and NEW YORK, March 12, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), a clinical-stage biopharmaceutical company developing innovative combination therapies, today announced an enhanced clinical development strategy for IHL-42X, its lead oral drug candidate for the treatment of obstructive sleep apnea (OSA), following statistically significant outcomes across key endpoints in its completed Phase 2 program. Importantly, IHL-42X has been granted Fast Track Designation by the U.S. Food and Drug Administration (FDA), enabling more frequent interaction with the FDA as the program advances. The updated development strategy includes a Phase 2 crossover dose-optimization study (DReAMzz), followed by a streamlined Phase 3 clinical program. This strategy is designed to optimize efficacy, strengthen the clinical data package, and potentially accelerate the pathway toward registration while maintaining strong capital efficiency. “Following the strong, statistically significant outcomes from our Phase 2 RePOSA trial, we believe IHL-42X is emerging as one of the most promising oral therapies in development for obstructive sleep apnea,” said Joel Latham, President and Chief Executive Officer of Incannex Healthcare. “The optimization study we are initiating is designed to further refine the drug’s efficacy while strengthening the clinical package ahead of Phase 3. We believe the optimized study design provides a pathway that could accelerate development timelines, potentially shorten time to registration if successful, and allow us to progress efficiently through the end of Phase 3 development.” Phase 2 Results Demonstrate Broad Clinical BenefitData from the completed RePOSA Phase 2 trial demonstrated that IHL-42X achieved statistically significant and clinically meaningful improvements across both objective physiological measures and patient-reported outcomes, reinforcing the therapeutic potential of the drug in OSA. RePOSA demonstrated: 33.3% of patients in low-dose group and 41.2% in high-dose group achieved greater than 30% reduction in apnea-hypopnea index (AHI), while 13.9% (low-dose) and 14.7% (high-dose) experienced reductions exceeding 50%Maximum of 83% and 79% reduction in AHI ...